Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Chih‐Hung Hsu, Toshihiko Doi et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Shukui Qin et al.|Journal of Clinical Oncology|2013Cited by 775
Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinomaYu‐Yun Shao, Chih‐Hung Hsu|Biology Direct|2025Cited by 2